Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: A nested case-control study

Journal of Rheumatology

Volumn 41, Issue 11, 2014, Pages 2129-2136

  Desai, Rishi J ^a,b   Rao, Jaya K ^b   Hansen, Richard A ^a   Fang, Gang ^c   Maciejewski, Matthew ^b   Farley, Joel ^a  

^a University of North Carolina   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c AUBURN UNIVERSITY   (United States)

Author keywords

Cardiovascular diseases; Early rheumatoid arthritis; Nested case control study; TNF inhibitors

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; FEMALE; GENDER; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; AGE DISTRIBUTION; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; COMPARATIVE STUDY; FOLLOW UP; MIDDLE AGED; MULTIVARIATE ANALYSIS; SEVERITY OF ILLNESS INDEX; SEX RATIO; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; AGE DISTRIBUTION; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84923227881     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.131464     Document Type: Article

References (34)

1. Maradit-Kremers H, Crowson CS, Nicola P.J., Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52:402-11.
2. Solomon DH, Karlson EW, Rimm E.B., Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107:1303-7.
3. Fischer LM, Schlienger RG, Matter C, Jick H., Meier CR. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 2004; 93:198-200.
4. del Rincón I, O'Leary DH, Freeman GL, Escalante A. Acceleration of atherosclerosis during the course of rheumatoid arthritis. Atherosclerosis 2007; 195:35460.
5. Aubry MC, Maradit-Kremers H, Reinalda M.S., Crowson CS, Edwards WD, Gabriel SE. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol 2007; 34:93742.
6. Dixon WG, Symmons DP. What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. Ann Rheum Dis 2007; 66:1132-6.
7. Jacobsson LT, Turesson C, Gulfe A., Kapetanovic MC, Petersson IF, Saxne T, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol 2005; 32:1213-18.
8. Nadareishvili Z, Michaud K, Hallenbeck J.M., Wolfe F. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum 2008; 59:1090-6.
9. Naranjo A, Sokka T, Descalzo M.A., Calvo-Alén J, Horslev-Petersen K, Luukkainen RK, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008; 10:R30.
10. Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum 2006; 55:531-6.
11. Al-Aly Z, Pan H, Zeringue A., Xian H, McDonald JR, El-Achkar TM, et al. Tumor necrosis factor-alpha blockade, cardiovascular outcomes, and survival in rheumatoid arthritis. Transi Res 2011; 157:10-18.
12. Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum 2008; 58:2612-21.
13. Dixon WG, Watson KD, Lunt M, Hyrich K.L., Silman AJ, Symmons DP. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologies Register. Arthritis Rheum 2007; 56:2905-12.
14. Singh G, Vadhavkar S, Mithal A., Triadafilopoulos G. Combination TNF-inhibitor-methotrexate therapy is superior to methotrexate monotherapy in reducing the risk of acute myocardial infarction in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56:S535.
15. Solomon DH, Avorn J, Katz J.N., Weinblatt ME, Setoguchi S, Levin R, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:3790-8.
16. Greenberg JD, Kremer JM, Curtis J.R., Hochberg MC, Reed G, Tsao P, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70:576-82.
17. Solomon DH, Curtis JR, Saag K.G., Lii J., Chen L, Harrold LR, et al. Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs. Am J Med 2013; 126:730.e9-730.e17.
18. Ljung L, Simard JF, Jacobsson L, Rantapaa-Dahlqvist S, Askling J., Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. Arthritis Rheum 2012; 64:42-52.
19. Fuchs HA, Kaye JJ, Callahan L.F., Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989; 16:585-91.
20. Kerola AM, Kauppi MJ, Kerola T, Nieminen TV. How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear? Ann Rheum Dis 2012; 71:1606-15.
21. Georgiadis AN, Papavasiliou EC, Lourida E.S., Alamanos Y., Kostara C, Tselepis AD, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment-a prospective, controlled study. Arthritis Res Ther 2006; 8:R82.
22. Georgiadis AN, Voulgari PV, Argyropoulou M.I., Alamanos Y., Elisaf M, Tselepis AD, et al. Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum 2008; 38:13-19.
23. Danielson E. Health research data for the real world: the MarketScan databases. White paper. January 2014. [Internet. Accessed June 20, 2014.] Available from: http://truvenhealth.eom/Portals/0/Users/031/31/31/PH-13434%200314JVIarketScan-WP-web.pdf
24. Etminan M. Pharmacoepidemiology II: the nested case-control study-a novel approach in pharmacoepidemiologic research. Pharmacotherapy 2004; 24:1105-9.
25. Hudson M, Suissa S. Avoiding common pitfalls in the analysis of observational studies of new treatments for rheumatoid arthritis. Arthritis Care Res 2010; 62:805-10.
26. Singh JA, Holmgren AR, Noorbaloochi S. Accuracy of Veterans Administration databases for a diagnosis of rheumatoid arthritis. Arthritis Rheum 2004; 51:952-7.
27. Rothman KJ. Epidemiology: an introduction. New York: Oxford University Press; 2002.
28. Strieker BH, Stijnen T. Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies. Eur J Epidemiol 2010; 25:245-51.
29. Mahonen M, Salomaa V, Brommels M., Molarius A, Miettinen H, Pyorala K., et al. The validity of hospital discharge register data on coronary heart disease in Finland. Eur J Epidemiol 1997; 13:403-15.
30. Pajunen P, Koukkunen H, Ketonen M., Jerkkola T, Immonen-Räihä P, Kärjä-Koskenkari P, et al. The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil 2005; 12:132-7.
31. Birman-Deych E, Waterman AD, Yan Y, Nilasena D.S., Radford MJ, Gage BF. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Medical Care 2005; 43:480-5.
32. Pascual-Ramos V, Contreras-Yanez I, Villa A.R., Cabiedes J., Rull-Gabayet M. Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability. Arthritis Res Ther 2009; 11:R26.
33. Solomon DH, Kremer J, Curtis J.R., Hochberg MC, Reed G, Tsao P, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010; 69:1920-5.
34. Grijalva CG, Chung CP, Arbogast P.G., Stein CM, Mitchel EF Jr, Griffin MR. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care 2007; 45:10 Suppl 2:S66-76.